OSE Immunotherapeutics - Tedopi remains focus in FY22
The pathway to regulatory approval for OSE’s neoepitope cancer vaccine, Tedopi, continues to be a key point of focus for the company. Following the...
670 Views
OSE Immunotherapeutics - Tedopi clinical data in NSCLC and PDAC
OSE Immunotherapeutics has highlighted recent clinical data for its multiple neoepitope cancer vaccine, Tedopi (OSE2101) at the American Society of...
669 Views
OSE Immunotherapeutics - First patient dosed with FR104/VEL-101
OSE Immunotherapeutics has announced that the first participant in a Phase I study has been dosed with the company’s CD28-targeting antibody...
441 Views
OSE Immunotherapeutics - Steady progress on all fronts
OSE Immunotherapeutics (OSE) and its three pharma partners have made progress with all key clinical and preclinical assets. The final analysis of...
9 Views
OSE Immunotherapeutics - Solid new details from Step 1 of Tedopi Ph III trial
On 21 September 2020, OSE presented additional data from step one of the Phase III Atalante 1 trial at the virtual ESMO conference. This followed...
165 Views